Delcath Systems' experimental drug-and-device combination for chemotherapy carries life-threatening risks that may outweigh any benefit, U.S. Food and Drug Administration staff said.
Delcath's chemotherapy device has risks, FDA staff says
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.